SNSE - Sensei Biotherapeutics Presents Promising SNS-101 Clinical Data at 2023 SITC Annual Meeting

2023-11-06 09:32:11 ET

DENVER, Colo., Nov 6, 2023 ( www.247marketnews.com )- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) presented, after Friday’s market close, initial monotherapy dose-escalation portion data from its Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaker poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data suggests a potential best-in-class safety and pharmacokinetic profile among VISTA blocking antibodies and the potential to overcome long-standing pharmacological challenges encountered by first generation approaches to blocking VISTA.

Sensei Biotherapeutics is trading at $0.7943, up 0.1043 (+15.12), on 307.9K premarket shares traded.

Its 52-week range is $0.51 to $1.926. Its next resistance point …

The post Sensei Biotherapeutics Presents Promising SNS-101 Clinical Data at 2023 SITC Annual Meeting appeared first on 24/7 Market News .

For further details see: